Members of the miR‑30 family inhibit the epithelial‑to‑mesenchymal transition of non‑small‑cell lung cancer cells by suppressing XB130 expression levels

Song,Kewei; Jiang,Yinhui; Zhao,Yan; Xie,Yuan; Zhou,Jianjiang; Yu,Wenfeng; Wang,Qinrong

doi:10.3892/ol.2020.11929

Members of the miR‑30 family inhibit the epithelial‑to‑mesenchymal transition of non‑small‑cell lung cancer cells by suppressing XB130 expression levels

Authors:
- Kewei Song
- Yinhui Jiang
- Yan Zhao
- Yuan Xie
- Jianjiang Zhou
- Wenfeng Yu
- Qinrong Wang
View Affiliations

Affiliations: College of Sport and Health and Key Laboratory of Endemic and Ethnic Diseases of The Ministry of Education, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China, College of Sport and Health and Key Laboratory of Endemic and Ethnic Diseases of the Ministry of Education, Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China
Published online on: July 29, 2020 https://doi.org/10.3892/ol.2020.11929
Article Number: 68
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRs) are associated with cancer metastasis. Aberrant expression levels of members of the miR‑30 family have been observed in non‑small‑cell lung cancer (NSCLC). However, the effects of miR‑30 family members on the epithelial‑to‑mesenchymal transition (EMT) of NSCLC cells and the underlying molecular mechanisms have not yet been fully elucidated. The present study investigated the effects of miR‑30 family members on EMT, migration and invasion of NSCLC cells and found that overexpression of these miRs inhibited EMT via decreasing the expression levels of N‑cadherin, β‑catenin and SNAI1, along with weakened migration and invasion abilities. Then, XB130 was identified as a downstream target of the miR‑30 family members. XB130‑knockdown also inhibited EMT of NSCLC cells, whereas ectopic overexpression of XB130 partly rescued the suppressive effects of miR‑30c and miR‑30d on EMT. In conclusion, miR‑30 family members inhibited EMT of NSCLC cells, partially via suppressing XB130 expression levels.

View Figures

View References

1	American Cancer Society, . Global cancer facts & figures. 4th. Atlanta: American Cancer Society; 2018
2	Mao Y, Yang D, He J and Krasna MJ: Epidemiology of lung cancer. Surg Oncol Clin N Am. 25:439–445. 2016. View Article : Google Scholar : PubMed/NCBI
3	Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, et al: immune cell composition in human non-small cell lung cancer. Front Immunol. 9:31012019. View Article : Google Scholar : PubMed/NCBI
4	Rong B and Yang S: Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review). Int J Oncol. 52:321–336. 2018.PubMed/NCBI
5	Li S, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Chen Y, Li W, Yang J and Han X: Role of microRNAs in metastasis of non-small cell lung cancer. Front Biosci (Landmark Ed). 21:998–1005. 2016. View Article : Google Scholar : PubMed/NCBI
6	Wood SL, Pernemalm M, Crosbie PA and Whetton AD: The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 40:558–566. 2014. View Article : Google Scholar : PubMed/NCBI
7	Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H: MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer. 130:2044–2053. 2012. View Article : Google Scholar : PubMed/NCBI
8	Iderzorig T, Kellen J, Osude C, Singh S, Woodman JA, Garcia C and Puri N: Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res Commun. 496:770–777. 2018. View Article : Google Scholar : PubMed/NCBI
9	Li J, Wang Q, Wen R, Liang J, Zhong X, Yang W, Su D and Tang J: MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med. 19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
10	Vishnoi A and Rani S: MiRNA biogenesis and regulation of diseases: An overview. Methods Mol Biol. 1509:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zhong K, Chen K, Han L and Li B: MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. BMC Cancer. 14:7032014. View Article : Google Scholar : PubMed/NCBI
12	Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang L, Liu L, Huang S, Zhao Y and He X: MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. Cancer Lett. 362:208–217. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhong Z, Xia Y, Wang P, Liu B and Chen Y: Low expression of microRNA-30c promotes invasion by inducing epithelial mesenchymal transition in non-small cell lung cancer. Mol Med Rep. 10:2575–2579. 2014. View Article : Google Scholar : PubMed/NCBI
14	Xu G, Cai J, Wang L, Jiang L, Huang J, Hu R and Ding F: MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling. Exp Cell Res. 362:268–278. 2018. View Article : Google Scholar : PubMed/NCBI
15	Li J, Sun W, Wei H, Wang X, Li H and Yi Z: Expression of XB130 in human ductal breast cancer. Int J Clin Exp Pathol. 8:5300–5308. 2015.PubMed/NCBI
16	Wang X, Wang R, Liu Z, Hao F, Huang H and Guo W: XB130 expression in human osteosarcoma: A clinical and experimental study. Int J Clin Exp Pathol. 8:2565–2573. 2015.PubMed/NCBI
17	Shiozaki A, Kosuga T, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Shimizu H, Ishimoto T, et al: XB130 as an independent prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol. 20:3140–3150. 2013. View Article : Google Scholar : PubMed/NCBI
18	Chen B, Liao M, Wei Q, Liu F, Zeng Q, Wang W and Liu J, Hou J, Yu X and Liu J: XB130 is overexpressed in prostate cancer and involved in cell growth and invasion. Oncotarget. 7:59377–59387. 2016. View Article : Google Scholar : PubMed/NCBI
19	Shi M, Zheng D, Sun L, Wang L, Lin L, Wu Y, Zhou M and Liao W, Liao Y, Zuo Q and Liao W: XB130 promotes proliferation and invasion of gastric cancer cells. J Transl Med. 12:12014. View Article : Google Scholar : PubMed/NCBI
20	Li GM, Liang CJ, Zhang DX, Zhang LJ, Wu JX and Xu YC: XB130 knockdown inhibits the proliferation, invasiveness, and metastasis of hepatocellular carcinoma cells and sensitizes them to TRAIL-induced apoptosis. Chin Med J (Engl). 131:2320–2331. 2018. View Article : Google Scholar : PubMed/NCBI
21	Shiozaki A, Lodyga M, Bai XH, Nadesalingam J, Oyaizu T, Winer D, Asa SL, Keshavjee S and Liu M: XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol. 178:391–401. 2011. View Article : Google Scholar : PubMed/NCBI
22	Xie T, Jiang C, Dai T, Xu R, Zhou X, Su X and Zhao X: Knockdown of XB130 restrains cancer stem cell-like phenotype through inhibition of Wnt/β-Catenin signaling in breast cancer. Mol Carcinog. 58:1832–1845. 2019. View Article : Google Scholar : PubMed/NCBI
23	Cho HR, Wang Y, Bai X, Xiang YY, Lu C, Post A, Al Habeeb A and Liu M: XB130 deficiency enhances carcinogen-induced skin tumorigenesis. Carcinogenesis. 40:1363–1375. 2019. View Article : Google Scholar : PubMed/NCBI
24	Wang Q, Yang G, Jiang Y, Luo M, Li C, Zhao Y, Xie Y, Song K and Zhou J: XB130, regulated by miR-203, miR-219, and miR-4782-3p, mediates the proliferation and metastasis of non-small-cell lung cancer cells. Mol Carcinog. 59:557–568. 2020. View Article : Google Scholar : PubMed/NCBI
25	Takeshita H, Shiozaki A, Bai XH, Iitaka D, Kim H, Yang BB, Keshavjee S and Liu M: XB130, a new adaptor protein, regulates expression of tumor suppressive microRNAs in cancer cells. PLoS One. 8:e590572013. View Article : Google Scholar : PubMed/NCBI
26	Fazilaty H, Rago L, Kass Youssef K, Ocaña OH, Garcia-Asencio F, Arcas A, Galceran J and Nieto MA: A gene regulatory network to control EMT programs in development and disease. Nat Commun. 10:51152019. View Article : Google Scholar : PubMed/NCBI
27	Shukla V, Adiga D, Jishnu PV, Varghese VK, Satyamoorthy K and Kabekkodu SP: Role of miRNA clusters in epithelial to mesenchymal transition in cancer. Front Biosci (Elite Ed). 12:48–78. 2020.PubMed/NCBI
28	Atambayeva S, Niyazova R, Ivashchenko A, Pyrkova A, Pinsky I, Akimniyazova A and Labeit S: The binding sites of miR-619-5p in the mRNAs of human and orthologous genes. BMC Genomics. 18:4282017. View Article : Google Scholar : PubMed/NCBI
29	Kelly TJ, Suzuki HI, Zamudio JR, Suzuki M and Sharp PA: Sequestration of microRNA-mediated target repression by the Ago2-associated RNA-binding protein FAM120A. RNA. 25:1291–1297. 2019. View Article : Google Scholar : PubMed/NCBI
30	Zheng Z, Reichel M, Deveson I, Wong G, Li J and Millar AA: Target RNA secondary structure is a major determinant of miR159 efficacy. Plant Physiol. 174:1764–1778. 2017. View Article : Google Scholar : PubMed/NCBI
31	Bai XH, Cho HR, Moodley S and Liu M: XB130-a novel adaptor protein: Gene, function, and roles in tumorigenesis. Scientifica (Cairo). 2014:9030142014.PubMed/NCBI
32	Zhang J, Jiang X and Zhang J: Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma. World J Surg Oncol. 12:492014. View Article : Google Scholar : PubMed/NCBI
33	Shiozaki A, Shen-Tu G, Bai X, Iitaka D, De Falco V, Santoro M, Keshavjee S and Liu M: XB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt. PLoS One. 7:e436462012. View Article : Google Scholar : PubMed/NCBI
34	Yamanaka D, Akama T, Chida K, Minami S, Ito K, Hakuno F and Takahashi S: Phosphatidylinositol 3-kinase-associated protein (PI3KAP)/XB130 crosslinks actin filaments through its actin binding and multimerization properties in vitro and enhances endocytosis in HEK293 cells. Front Endocrinol (Lausanne). 7:892016. View Article : Google Scholar : PubMed/NCBI
35	Lodyga M, Xhi C, Anraku M, Liu N, Tsao M and Liu M: P-080 Prognostic expression of a novel adaptor protein XB130 in non-small-cell lung cancer. Lung Cancer. 49 (Suppl 2):S1352005. View Article : Google Scholar
36	Luan N, Wang Y and Liu X: Absent expression of miR-30a promotes the growth of lung cancer cells by targeting MEF2D. Oncol Lett. 16:1173–1179. 2018.PubMed/NCBI
37	Li G, Fang J, Wang Y, Wang H and Sun CC: MiRNA-based therapeutic strategy in lung cancer. Curr Pharm Des. 23:6011–6018. 2018. View Article : Google Scholar : PubMed/NCBI
38	Shiozaki A and Liu M: Roles of XB130, a novel adaptor protein, in cancer. J Clin Bioinforma. 1:102011. View Article : Google Scholar : PubMed/NCBI
39	Xu J, Bai XH, Lodyga M, Han B, Xiao H, Keshavjee S, Hu J, Zhang H, Yang BB and Liu M: XB130, a novel adaptor protein for signal transduction. J Biol Chem. 282:16401–16412. 2007. View Article : Google Scholar : PubMed/NCBI